ZS Pharma announces publication of results from phase 3 study of ZS-9 in NJEM
ZS Pharma announced publication of unreleased detailed results from the ZS003 study in the New England Journal of Medicine. ZS003 was a Phase 3, 753 patient, multicenter, randomized, double-blind, placebo-controlled trial that assessed safety and efficacy of ZS-9 in treating hyperkalemia. November 21, 2014